Core Viewpoint - The company, Zhixiang Jintai, has signed exclusive cooperation agreements with Kangzhe Pharmaceutical and RXILIENT for the commercialization of two monoclonal antibody injections, GR2001 and GR1801, which will provide significant financial benefits and market access in various regions [1][2][3] Group 1: Agreements and Financial Terms - The agreements grant exclusive commercialization rights for GR2001 to Tibet Kangzhe in mainland China, while RXILIENT receives exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa [1] - Zhixiang Jintai will receive upfront and milestone payments totaling up to approximately 260 million RMB for GR2001, along with revenue from sales in mainland China and supply income based on net sales in other regions [1] - For GR1801, Tibet Kangzhe will also obtain exclusive commercialization rights in mainland China, with RXILIENT securing similar rights in the Asia-Pacific region and the Middle East and North Africa, and Zhixiang Jintai will receive payments up to approximately 250 million RMB [2] Group 2: Product Details - GR2001 is a recombinant humanized monoclonal antibody targeting the C-terminal of the Tetanus Neurotoxin (TeNT), classified as a Class 1 therapeutic biological product, providing passive immunity by blocking TeNT from entering neuronal cells [2] - GR1801 is a recombinant fully human bispecific antibody targeting the glycoprotein of the Rabies Virus (RABV), also classified as a Class 1 therapeutic biological product, designed to prevent rabies by blocking the virus's interaction with receptors before the vaccine can take effect [3]